Back to Search Start Over

Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials.

Authors :
Hong H
Friedland A
Hu M
Anstrom KJ
Halabi S
McKinnon JE
Amaravadi R
Rojas-Serrano J
Abella BS
Portillo-Vázquez AM
Woods CW
Hernandez AF
Boulware DR
Naggie S
Rajasingham R
Source :
BMJ open [BMJ Open] 2023 Jun 16; Vol. 13 (6), pp. e065305. Date of Electronic Publication: 2023 Jun 16.
Publication Year :
2023

Abstract

Objective: We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs).<br />Data Sources: PubMed and EMBASE databases were searched to identify randomised trials studying HCQ.<br />Study Selection: Ten RCTs were identified (n=5079 participants).<br />Data Extraction and Synthesis: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used in this systematic review and meta-analysis between HCQ and placebo using a Bayesian random-effects model. A pre-hoc statistical analysis plan was written.<br />Main Outcomes: The primary efficacy outcome was PCR-confirmed SARS-CoV-2 infection and the primary safety outcome was incidence of adverse events. The secondary outcome included clinically suspected SARS-CoV-2 infection.<br />Results: Compared with placebo, HCWs randomised to HCQ had no significant difference in PCR-confirmed SARS-CoV-2 infection (OR 0.92, 95% credible interval (CI): 0.58, 1.37) or clinically suspected SARS-CoV-2 infection (OR 0.78, 95% CI: 0.57, 1.10), but significant difference in adverse events (OR 1.35, 95% CI: 1.03, 1.73).<br />Conclusions and Relevance: Our meta-analysis of 10 RCTs investigating the safety and efficacy of HCQ as pre-exposure prophylaxis in HCWs found that compared with placebo, HCQ does not significantly reduce the risk of confirmed or clinically suspected SARS-CoV-2 infection, while HCQ significantly increases adverse events.<br />Prospero Registration Number: CRD42021285093.<br />Competing Interests: Competing interests: All authors except BSA reported no financial relationship with commercial interest. BSA has received NIH funds for COVID-19-related research and holds equity in VOC Health, a start-up company that is developing novel COVID-19 testing.<br /> (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Details

Language :
English
ISSN :
2044-6055
Volume :
13
Issue :
6
Database :
MEDLINE
Journal :
BMJ open
Publication Type :
Academic Journal
Accession number :
37328184
Full Text :
https://doi.org/10.1136/bmjopen-2022-065305